Biological
Oncophage clinical trials
Also written HSPPC-96 and vitespen.
- studies test it
- 11
- open now
- 0
- in phase 3
- 2
- first study started
- 1997
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2005 (2)
| Year | Studies |
|---|---|
| 1997 | 1 |
| 1999 | 1 |
| 2002 | 1 |
| 2003 | 1 |
| 2005 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 1 |
| 2015 | 1 |
| 2017 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 8
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 7
Agenus Inc. (4) · University of California, San Francisco (2) · Memorial Sloan Kettering Cancer Center (2) · National Cancer Institute (NCI) (1) · Alliance for Clinical Trials in Oncology (1) · Rabih Said (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses oncophage is read from its arms, and is right about nine times in ten.
Testing it · 11
- Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)TerminatedPhase 2National Cancer Institute (NCI)NCT03018288Written as HSPPC-96
- Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by SurgeryTerminatedPhase 2Alliance for Clinical Trials in OncologyNCT01814813Written as HSPPC-96
- Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of RecurrenceTerminatedPhase 2Agenus Inc.NCT01147536Written as HSPPC-96
- GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive GliomaCompletedPhase 1/2University of California, San FranciscoNCT00293423Written as HSPPC-96
- HSPPC-96 Vaccine With Temozolomide in Patients With Newly Diagnosed GBMCompletedPhase 2University of California, San FranciscoNCT00905060Written as HSPPC-96
- Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced MelanomaWithdrawnPhase 1/2Rabih SaidNCT02452281Written as HSPPC-96
- Vaccine Therapy in Treating Patients With Stage I or Stage II Pancreatic CancerCompletedPhase 1Memorial Sloan Kettering Cancer CenterNCT00003025Written as vitespen
- Vaccine Therapy in Treating Patients With Recurrent Soft Tissue SarcomaCompletedPhase 2Memorial Sloan Kettering Cancer CenterNCT00005628Written as vitespen
- Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV MelanomaCompletedPhase 3Agenus Inc.NCT00039000Written as HSPPC-96 or Oncophage
- Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney CancerTerminatedPhase 3Agenus Inc.NCT00126178Written as HSPPC-96
- Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung CancerCompletedPhase 2Agenus Inc.NCT00098085Written as HSPPC-96
Given in every arm · 1 — oncophage is usual care beside what is tested
Codes
What other systems call oncophage · ClinicalTrials.gg INT016733
- UNII (FDA) H3598Y1TLJVITESPENConfirmed FDA, Wikidata
- Wikidata Q7092116oncophageConfirmed FDA, Wikidata
- DrugBank DB06400One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | H3598Y1TLJ | VITESPEN | Confirmed FDA, Wikidata |
| Wikidata | Q7092116 | oncophage | Confirmed FDA, Wikidata |
| DrugBank | DB06400 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.